# Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

> **NCT05577182** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 46 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** INCA32459-101

## Key facts

- **NCT ID:** NCT05577182
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-05
- **Primary completion:** 2025-10-13
- **Final completion:** 2025-10-13
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05577182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05577182, "Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05577182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*